AR106307A1 - Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos - Google Patents

Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos

Info

Publication number
AR106307A1
AR106307A1 ARP160103089A ARP160103089A AR106307A1 AR 106307 A1 AR106307 A1 AR 106307A1 AR P160103089 A ARP160103089 A AR P160103089A AR P160103089 A ARP160103089 A AR P160103089A AR 106307 A1 AR106307 A1 AR 106307A1
Authority
AR
Argentina
Prior art keywords
amino acid
substituted
basic
binding portion
antigen binding
Prior art date
Application number
ARP160103089A
Other languages
English (en)
Spanish (es)
Original Assignee
Obi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc
Publication of AR106307A1 publication Critical patent/AR106307A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP160103089A 2015-10-07 2016-10-07 Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos AR106307A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562238680P 2015-10-07 2015-10-07

Publications (1)

Publication Number Publication Date
AR106307A1 true AR106307A1 (es) 2018-01-03

Family

ID=58488607

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103089A AR106307A1 (es) 2015-10-07 2016-10-07 Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos

Country Status (12)

Country Link
US (2) US10501532B2 (enExample)
EP (1) EP3359193A4 (enExample)
JP (1) JP2018536628A (enExample)
KR (1) KR20180077181A (enExample)
CN (1) CN108472362B (enExample)
AR (1) AR106307A1 (enExample)
AU (1) AU2016335842A1 (enExample)
BR (1) BR112018006140A2 (enExample)
CA (1) CA3000531A1 (enExample)
IL (1) IL257956A (enExample)
TW (1) TWI704159B (enExample)
WO (1) WO2017062792A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2666141C2 (ru) 2013-09-17 2018-09-06 Оби Фарма, Инк. Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20250048399A (ko) 2016-04-22 2025-04-08 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
EP3491026A4 (en) 2016-07-29 2020-07-29 OBI Pharma, Inc. HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES
JP2019535731A (ja) 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド コンジュゲートさせた生物学的分子、医薬組成物及び方法
TWI714854B (zh) * 2017-05-24 2021-01-01 財團法人生物技術開發中心 抗globo h之人類化抗體及其於治療癌症之用途
CA3092002A1 (en) * 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
WO2019232519A1 (en) * 2018-06-01 2019-12-05 Obi Pharma, Inc. Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members
CN116589572B (zh) * 2023-06-28 2023-11-10 湖南诺合新生物科技有限公司 一种抗ha标签的单克隆抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2006084050A2 (en) * 2005-02-01 2006-08-10 Dyax Corp. Libraries and methods for isolating antibodies
US20100082438A1 (en) 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
TWI392502B (zh) * 2009-06-16 2013-04-11 Academia Sinica 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗
US8481687B2 (en) * 2010-04-09 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
WO2013006449A2 (en) * 2011-07-01 2013-01-10 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
WO2015015629A1 (ja) 2013-08-02 2015-02-05 株式会社日立製作所 炭化珪素半導体装置および炭化珪素半導体装置の製造方法
CN104693305A (zh) * 2013-12-04 2015-06-10 苏州中赢医疗科技有限公司 一种抗人鞘糖脂Globo-H单克隆抗体、其制备方法及应用
MX2016012124A (es) * 2014-03-19 2017-04-06 Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CA3104268A1 (en) * 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
HK1256414A1 (zh) 2019-09-20
WO2017062792A1 (en) 2017-04-13
TW201718658A (zh) 2017-06-01
AU2016335842A1 (en) 2018-04-12
CN108472362A (zh) 2018-08-31
US10501532B2 (en) 2019-12-10
BR112018006140A2 (pt) 2018-10-23
US11236154B2 (en) 2022-02-01
US20200048334A1 (en) 2020-02-13
CA3000531A1 (en) 2017-04-13
CN108472362B (zh) 2022-03-29
EP3359193A4 (en) 2019-05-08
IL257956A (en) 2018-06-28
KR20180077181A (ko) 2018-07-06
US20170101462A1 (en) 2017-04-13
JP2018536628A (ja) 2018-12-13
TWI704159B (zh) 2020-09-11
EP3359193A1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
AR127371A2 (es) Receptores quiméricos de flt3 y métodos para usarlos
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
BR112019003775A2 (pt) anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
PE20190737A1 (es) Anticuerpos anti-cd27
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
PH12016502590B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
AR096617A1 (es) Anticuerpos anti-tweakr y sus usos
MX2018007406A (es) Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
EA201791270A1 (ru) Модифицированные april-связывающие антитела
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure